Tracey MullenChief Operating Officer at Abveris and AbX Biologics at Abveris Antibody
Tracey Mullen is a chemical-biological engineer from MIT who began her career as an Antibody Discovery Scientist at a startup contract research organization specializing in in vivo antibody discovery. In 2013, she joined the Antibody Discovery team at Biogen where she helped implement the technology transfer of the Adimab yeast display platform for antibody discovery and engineering. Throughout her tenure at Biogen, Tracey worked to optimize the in vitro discovery of antibodies to tough targets, including leveraging the Adimab platform to generate antibodies against GPCRs. In June of 2018, Tracey joined Abveris Antibody as the Director of Antibody Discovery Operations, where she managed project design and development for in vivo discovery projects. She is now the Chief Operating Officer at AbX Biologics (formerly Abveris), a premium antibody discovery service partner boasting industry-leading timelines and cutting-edge technologies.